Zentylor tideglusib regulatory update

FDA granted Fast Track designation for Noscira's Zentylor tideglusib to treat progressive supranuclear palsy (PSP). The glycogen dependent kinase 3 (GSK3) inhibitor is in Phase II testing for the ind...